The clinical utility of a multivariate genetic panel for identifying those at risk of developing Opioid Use Disorder while on prescription opioids

Paul Swamidhas Sudhakar Russell 1
  • 1 Department of Psychiatry, Child and Adolescent Psychiatry Unit, Christian Medical College, Vellore, Tamil Nadu, India
Paul Swamidhas Sudhakar Russell
  • Corresponding author
  • Department of Psychiatry, Child and Adolescent Psychiatry Unit, Christian Medical College, Vellore, Tamil Nadu, India
  • Email
  • Search for other articles:
  • degruyter.comGoogle Scholar

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1]

    Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014;71:821–6.

    • Crossref
    • PubMed
    • Export Citation
  • [2]

    Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:569–76.

    • Crossref
    • PubMed
    • Export Citation
  • [3]

    GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1603–58.

    • PubMed
    • Export Citation
  • [4]

    Donaldson K, Demers L, Taylor K, Lopez J, Chang S. Multi-variant genetic panel for genetic risk of opioid addiction. Ann Clin Lab Sci 2017;47:452–6.

    • PubMed
    • Export Citation
  • [5]

    Mitchell AJ. Sensitivity×PPV is a recognized test called the clinical utility index (CUI+). Eur J Epidemiol 2011;26:251–2.

    • Crossref
    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Search